GLP-1 medications and PCOS weight loss: what TikTok gets wrong

What did @lizdamyl actually say?

She said she gained 40 pounds over roughly seven months after stopping her GLP-1 medication consistently, skipping weeks at a time, eating poorly, and not hitting her protein targets. Her conclusion: "this is a tool to help you get where you need to be, but you need to make the lifestyle changes or else it's worthless." She's now restarting at 205 pounds on 15 mg of compounded tirzepatide from a telehealth provider called Ivean Health.

That's the core claim: weight regain after GLP-1 discontinuation or inconsistent use is real, predictable, and partly self-inflicted if you stop doing the behavioral work. She's owning it publicly, which is unusual and worth credit.

Does the science back this up?

Yes, and the data is uncomfortable for anyone who thought these medications were a permanent fix. The evidence on weight regain after GLP-1 cessation is consistent and significant.

The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest example: participants who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. A follow-up analysis of tirzepatide from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar patterns, with placebo-switchers regaining roughly half their lost weight within 52 weeks compared to those who continued treatment.

What @lizdamyl experienced, going weeks without doses and not maintaining dietary habits, would logically accelerate that regain. GLP-1 agonists work partly by suppressing appetite and slowing gastric emptying. Stop the drug intermittently and inconsistently, and you lose those effects without any stable baseline to fall back on.

What did she get wrong, or right?

She got the big picture right. The framing that GLP-1s are "a tool" and not a substitute for behavioral change is accurate and consistent with how endocrinologists and obesity medicine specialists talk about these medications in clinical practice.

Where it gets messier: she calls her medication "trisepitide," which appears to be a mispronunciation of tirzepatide. Minor, but worth flagging because medication name accuracy matters when millions of people are searching these terms online.

More importantly, she doesn't mention she's using a compounded version of tirzepatide. Compounded tirzepatide is not FDA-approved, and the FDA has stated that compounded drugs are not demonstrated to be safe, effective, or equivalent to their brand-name counterparts. FormBlends and any responsible platform will tell you: compounded is not the same as Zepbound or Mounjaro. Period. That distinction matters for safety and for setting realistic expectations.

• Her weight loss journey numbers are plausible and internally consistent.
• Her explanation of why she regained is honest and matches the pharmacology.
• She does not overclaim what the drug does or promise outcomes to viewers.

What should you actually know?

Weight regain after GLP-1 discontinuation is not a personal failure unique to her. It's a documented pharmacological reality. These medications appear to require ongoing use for sustained effect in most people, similar to how antihypertensives require continued use to control blood pressure.

The behavioral component she describes, protein intake, hydration, consistent dosing, is real. Research from Wilding et al. (2021, NEJM) on semaglutide showed that participants who combined the drug with lifestyle intervention retained more benefit. But lifestyle changes alone couldn't fully compensate for stopping the medication in most subjects.

If you're considering a GLP-1 medication, ask your prescriber directly: what happens if I stop? What's the plan long-term? And if you're getting compounded tirzepatide specifically, ask about the source, concentration, and what quality controls are in place. Those are not paranoid questions. They are standard ones.